Moderna's updated COVID-19 mRNA vaccine will be available for the 2025-2026 vaccination season, pending a European Commission authorization decision
The agency concluded that for people of all ages, IXCHI should be administered when there is a significant risk of chikungunya infection
Spikevax is now approved for all individuals aged 6 months through 64 years at increased risk for COVID-19 disease
The company has confirmed that the deceased are 39
mRNA-1010 demonstrated superior relative vaccine efficacy
The merged entity ‘Aster DM Quality Care’ will be jointly controlled by Aster Promoters and Blackstone
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
This termination of Agreement will not have any significant impact on the company and/or its subsidiaries or its financials
Zydus will carry out early-stage development, animal immunogenicity studies and regulatory preclinical toxicology studies for this combination vaccine
No safety signals related to the vaccine candidate were identified
Subscribe To Our Newsletter & Stay Updated
